Overview

Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

Status:
Completed

Trial end date:
2007-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of three dose levels of combretastatin A4 phosphate (CA4P) given intravenously (IV) in combination with bevacizumab every 14 days in patients with advanced solid tumors. The maximum tolerated dose will be defined if it is at one of the three dose levels under study.

Phase:

Phase 1

Details

Lead Sponsor:

Mateon Therapeutics

Treatments:

Bevacizumab
Combretastatin
Fosbretabulin